Cellular Immune Response to an Engineered Cell-based Tumor Vaccine at the Vaccination Site

Overview

Journal Cell Immunol

Publisher Elsevier

Specialties Allergy & Immunology
Cell Biology

Date 2007 Jun 5

PMID 17543914

Citations 2

Authors

Qiang Zhou

Bryon D Johnson

Rimas J Orentas

Affiliations

Soon will be listed here.

Abstract

The engineered expression of the immune co-stimulatory molecules CD80 and CD137L on the surface of a neuroblastoma cell line converts this tumor into a cell-based cancer vaccine. The mechanism by which this vaccine activates the immune system was investigated by capturing and analyzing immune cells responding to the vaccine cell line embedded in a collagen matrix and injected subcutaneously. The vaccine induced a significant increase in the number of activated CD62L(-) CCR7(-) CD49b(+) CD8 effector memory T cells captured in the matrix. Importantly, vaccine responsive cells could be detected in the vaccine matrix within a matter of days as demonstrated by IFN-gamma production. The substitution of unmodified tumor cells for the vaccine during serial vaccination resulted in a significant decrease in activated T cells present in the matrix, indicating that immune responses at the vaccine site are a dynamic process that must be propagated by continued co-stimulation.

Citing Articles

Skin-Integrated Electrogenetic Regulation of Vasculature for Accelerated Wound Healing.

Guha Ray P, Rajasekaran R, Pratihar B, De S, Dhara S, Fussenegger M Adv Sci (Weinh). 2025; 12(9):e2412257.

PMID: 39792704 PMC: 11884547. DOI: 10.1002/advs.202412257.

Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity.

Barr K, Jing W, Hallett W, Gershan J, Johnson B J Immunother. 2012; 36(1):41-51.

PMID: 23211619 PMC: 3521867. DOI: 10.1097/CJI.0b013e318274590e.

Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo.

Zhou Q, Yan X, Gershan J, Orentas R, Johnson B J Immunol. 2008; 181(3):1877-86.

PMID: 18641325 PMC: 3804024. DOI: 10.4049/jimmunol.181.3.1877.

References

Hemler M, Jacobson J, Strominger J . Biochemical characterization of VLA-1 and VLA-2. Cell surface heterodimers on activated T cells. J Biol Chem. 1985; 260(28):15246-52. View

Brenner M, Heslop H, Krance R, Horowitz M, Strother D, Nuchtern J . Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000; 11(10):1477-88. DOI: 10.1089/10430340050057549. View

Risso A, Smilovich D, Capra M, Baldissarro I, Yan G, Bargellesi A . CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression. J Immunol. 1991; 146(12):4105-14. View

Campanero M, Arroyo A, Pulido R, Ursa A, de Matias M, Sanchez-Mateos P . Functional role of alpha 2/beta 1 and alpha 4/beta 1 integrins in leukocyte intercellular adhesion induced through the common beta 1 subunit. Eur J Immunol. 1992; 22(12):3111-9. DOI: 10.1002/eji.1830221213. View

Bargatze R, Jutila M, Butcher E . Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. Immunity. 1995; 3(1):99-108. DOI: 10.1016/1074-7613(95)90162-0. View

Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo M, Lollini P . Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today. 1997; 18(1):32-6. DOI: 10.1016/s0167-5699(97)80012-6. View

Gunn M, Tangemann K, Tam C, Cyster J, Rosen S, Williams L . A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A. 1998; 95(1):258-63. PMC: 18193. DOI: 10.1073/pnas.95.1.258. View

Bowman L, Grossmann M, Rill D, Brown M, Zhong W, Alexander B . Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998; 9(9):1303-11. DOI: 10.1089/hum.1998.9.9-1303. View

Bowman L, Grossmann M, Rill D, Brown M, Zhong W, Alexander B . IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998; 92(6):1941-9. View

10.

Matthay K, Villablanca J, Seeger R, Stram D, Harris R, Ramsay N . Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341(16):1165-73. DOI: 10.1056/NEJM199910143411601. View

11.

Ito F, Li Q, Shreiner A, Okuyama R, Jure-Kunkel M, Teitz-Tennenbaum S . Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 2004; 64(22):8411-9. DOI: 10.1158/0008-5472.CAN-04-0590. View

12.

Greenwald R, Freeman G, Sharpe A . The B7 family revisited. Annu Rev Immunol. 2005; 23:515-48. DOI: 10.1146/annurev.immunol.23.021704.115611. View

13.

Corthay A, Skovseth D, Lundin K, Rosjo E, Omholt H, Hofgaard P . Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005; 22(3):371-83. DOI: 10.1016/j.immuni.2005.02.003. View

14.

Ebert L, Schaerli P, Moser B . Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol. 2005; 42(7):799-809. DOI: 10.1016/j.molimm.2004.06.040. View

15.

Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I . Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005; 201(8):1257-68. PMC: 2213151. DOI: 10.1084/jem.20042028. View

16.

Vance B, Harley P, Backlund P, Ward Y, Phelps T, Gress R . Human CD69 associates with an N-terminal fragment of calreticulin at the cell surface. Arch Biochem Biophys. 2005; 438(1):11-20. DOI: 10.1016/j.abb.2005.04.009. View

17.

Lee S, Ju S, Pack H, Heo S, Suh J, Park S . 4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection. Infect Immun. 2005; 73(8):5144-51. PMC: 1201223. DOI: 10.1128/IAI.73.8.5144-5151.2005. View

18.

Johnson B, Gershan J, Natalia N, Zujewski H, Weber J, Yan X . Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J Immunother. 2005; 28(5):449-60. DOI: 10.1097/01.cji.0000171313.93299.74. View

19.

Bachmann M, Wolint P, Schwarz K, Jager P, Oxenius A . Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol. 2005; 175(7):4686-96. DOI: 10.4049/jimmunol.175.7.4686. View

20.

Zhang L, Wang Q, Wang X, Ding P, Song J, Ma C . Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro. Cell Mol Immunol. 2005; 1(1):71-6. View